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Abstract
Objective
To investigate disease-specific foveal shape changes in patients with neuromyelitis optica
spectrum disorders (NMOSDs) using foveal morphometry.
Methods
This cross-sectional study included macular spectral domain optical coherence tomography
scans of 52 eyes from 28 patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-sero-
positive NMOSD, 116 eyes from 60 patients with MS, and 123 eyes from 62 healthy controls
(HCs), retrospectively, and an independent confirmatory cohort comprised 33/33 patients
with NMOSD/MS. The fovea was characterized using 3D foveal morphometry. We included
peripapillary retinal nerve fiber layer (pRNFL) thickness and combined macular ganglion cell
and inner plexiform layer (GCIPL) volume to account for optic neuritis (ON)-related neu-
roaxonal damage.
Results
Group comparison showed significant differences compared with HC in the majority of foveal
shape parameters in NMOSD, but not MS. Pit flat disk area, average pit flat disk diameter, inner
rim volume, and major slope disk length, as selected parameters, showed differences between
NMOSD and MS (p value = 0.017, 0.002, 0.005, and 0.033, respectively). This effect was
independent of ON. Area under the curve was between 0.7 and 0.8 (receiver operating char-
acteristic curve) for discriminating between NMOSD and MS. Pit flat disk area and average pit
flat disk diameter changes independent of ON were confirmed in an independent cohort.
Conclusions
Foveal morphometry reveals a wider and flatter fovea in NMOSD in comparison to MS and
HC. Comparison to MS and accounting for ON suggest this effect to be at least in part
independent of ON. This supports a primary retinopathy in AQP4-IgG–seropositive NMOSD.
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Aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive
neuromyelitis optica spectrum disorder (NMOSD) is an in-
flammatory astrocytopathy defined by pathogenic serum im-
munoglobulin G antibodies against aquaporin-4.1–3
Optic neuritis (ON) is a hallmark of NMOSD and leads to
severe neuroaxonal damage in optic nerve and retina associ-
ated with oftentimes severe vision loss.4–8 Retinal optical
coherence tomography (OCT) can be used to measure this
damage9–12: Peripapillary retinal nerve fiber layer (pRNFL)
and combined macular ganglion cell and inner plexiform layer
(GCIPL) typically become thinner, whereas inner nuclear
layer (INL) becomes thicker as a result of ON.6,13–15
Recently, a foveal thickness (FT) reduction has been reported
in eyes never experiencing an ON in patients with AQP4-
IgG–seropositive NMOSD,16,17 suggesting either subclinical
optic nerve inflammation or primary retinal astrocytopathy in
NMOSD.8 This change in FT appeared to be driven by
a change in foveal shape, with a normally V-shaped fovea
appearing more widened and U-shaped with flattened disk in
eyes of patients with AQP4-IgG–seropositive NMOSD.17
Because FT is a weak measure for foveal shape, we developed
a 3D foveal morphometry method, which we previously de-
scribed and validated in detail.18 Here, we use this approach to
investigate the foveal shape in patients with AQP4-
IgG–seropositive NMOSD. We compare findings against
measurements in patients with MS, which also presents with
ON, and against healthy controls (HCs). Our goal was to
investigate whether foveal changes are characteristic to AQP4-
IgG–seropositive NMOSD and not simply caused by ON.
Methods
Study population
In this analysis, we retrospectively included data from an
ongoing observational cohort study in patients with NMOSD
at the NeuroCure Clinical Research Center at Charite´—
Universita¨tsmedizin Berlin, Germany, acquired from August
2013 to November 2016. Inclusion criteria were a minimum age
of 18 years and fulfilling the diagnostic criteria for AQP4-
IgG–seropositive NMOSD according to the 2015 International
Consensus Diagnostic Criteria.7 AQP4-IgG–seropositivity
was tested using a cell-based assay (Euroimmun, Lu¨beck,
Germany). Exclusion criteria were any other neurologic or
ophthalmologic disorder (e.g., glaucoma, diabetes, and
refractive error >6 diopters), which can affect the retina.19
Eyes with an episode of ON within the last 6 months before
the OCT examinations were excluded. Of 46 patients
enclosed in the study, we included 28 patients with NMOSD
in the analysis after applying the inclusion and exclusion cri-
teria (table 1). We additionally included 60 patients with
relapsing-remitting MS according to the 2010 revised
McDonald criteria,20 from 2 cohort studies about MS and
clinically isolated syndrome and 62 HCs, both groups age and
sex matched to the NMOSD cohort, in this study (table 1).
Data from 17 patients with AQP4-IgG–seropositive NMOSD
(61%) were already included in a previous study by Oertel
et al.17 High-contrast visual acuity was measured using Early
Treatment in Diabetes Retinopathy Study charts at a 4-m
distance with an Optec 6500 P system (Stereo Optical, Chi-
cago, IL), with best correction and under photopic conditions.
A confirmatory cohort consisting of macular OCTs from 58
eyes of 33 patients with AQP4-IgG–seropositive NMOSD
(eyes with a history of ON [ON+]: 27; 33 women; age: 49.2 ±
15.4 years) and 62 eyes of 33 patients with MS (ON+: 12; 32
women; age: 49.7 ± 14.7 years) from longitudinal prospective
observational cohort studies at the Department of Neurology,
Universita¨tsklinikum Du¨sseldorf at Heinrich Heine University,
Du¨sseldorf, Germany, was included in this study, following the
same inclusion and exclusion criteria. MS and NMOSD groups
were well matched in this cohort for age (p = 0.812) and sex (p
= 1), but not for the proportion of eyes with ON (p = 0.001).
The NMOSD group is well matched to the Berlin cohort for
age (p = 0.113), sex (p = 0.214), and ON+ (p = 0.507).
Ethics statement
The study was approved by the local ethics committee at
Charite´—Universita¨tsmedizin Berlin (EA1/131/09, EA1/163/
12, and EA1/182/10). The confirmatory OCT data were col-
lected under approval from the local ethics committee at
Heinrich Heine University Du¨sseldorf (4389R). The study was
conducted according to the Declaration of Helsinki in its cur-
rently applicable version and the applicable German and Eu-
ropean laws. All the participants gave written informed consent.
Optical coherence tomography
All retinal OCT images (exploratory and confirmatory co-
hort) were taken using Spectralis spectral domain OCT
devices from Heidelberg Engineering (Heidelberg, Ger-
many), with activated eye tracker and automatic real-time
(ART) averaging. The pRNFL thickness was calculated using
standard ring scans around the optic nerve head (12°, single B
Glossary
AQP4-IgG = aquaporin-4 immunoglobulin G;ART = automatic real time;AUC = area under the curve;B = estimate; FT = foveal
thickness; GCIPL = combined macular ganglion cell and inner plexiform layer; HC = healthy control; ILM = inner limiting
membrane; INL = inner nuclear layer;MOG = myelin oligodendrocyte glycoprotein;NMOSD = neuromyelitis optica spectrum
disorder; OCT = optical coherence tomography; ON = optic neuritis; ON− = eyes without a history of ON; ON+ = eyes with
a history of ON; pRNFL = peripapillary retinal nerve fiber layer;ROC = receiver operating characteristic; SE = standard error of B.
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scan with 1536 A scans, 16 ≤ ART ≤100). The volume of the
GCIPL and INL was calculated in a 6-mm diameter around
the fovea, and FT was measured in a 1-mm-diameter area
around the fovea, based on macular volume scans (25° × 30°,
61 B scans with 768 A scans per each B scan, ART = 15).
Intraretinal layer segmentation was performed and corrected
if needed using Heidelberg Eye Explorer (HEYEX version
1.9.10.0) by an experienced grader. All OCT scans were
quality controlled according to the OSCAR-IB criteria,19,21
and OCT data are reported in accordance with the Advised
Protocol for OCT Study Terminology and Elements
(APOSTEL) recommendations.22 Four eyes from the ex-
ploratory cohort were excluded from the study because of
inadequate OCT scan quality.
Foveal morphometry
All macular volume OCTs were analyzed using a 3D foveal
morphometry described previously in detail.18 In brief, first,
the 3D macular scan is flattened based on the segmentation of
the Bruch membrane as the reference plane, and then the
inner limiting membrane (ILM) surface is smoothed and
reconstructed radially using a cubic Bezier polynomial model.
Based on the reconstructed ILM surface, several parameters
are defined to describe the foveal and parafoveal shape. Three
surfaces are defined in this foveal shape analysis method: rim
disk, which connects the points on the surface with the max-
imum height (rim points); slope disk, which connects the
points with the maximum slopes in the parafoveal area; and pit
flat disk, which characterizes the flatness of the foveal pit. Each
surface is described by 4 parameters—the length in the
dominant direction (major axis): major length; the length in
the second dominant direction (perpendicular to the major
axis): minor length; the area; and the average diameter. In
addition, the distance between the fovea (theminimum point)
and the center of rim disk: average pit depth; the distance
between the fovea and the reference plane: central foveal
thickness; the average height of the rim points: average rim
height; the volume between the ILM surface and the reference
plane: rim volume; the volume between the ILM surface and
rim disk: pit volume; the volume between the ILM surface and
the reference plane within 1-mm-diameter cylinder centered
at the fovea: inner rim volume; and the average slope at the
maximum slope points: average maximum pit slope are mea-
sured by this method to characterize the 3D foveal shape.
Figure 1 gives an overview of the method and the defined
parameters. Test-retest reliability was excellent in all foveal
morphometry parameters with intraclass correlation coef-
ficients >0.9 in all cases (table e-1, links.lww.com/NXI/A270).
Statistical analysis
Sex and ON differences between groups were tested using χ2
tests, and age differences were tested using 2-sample Wil-
coxon tests. Performance measurements were based on the
area under the curve (AUC) for receiver operating
Table 1 Demographic description of NMOSD, MS, and HC cohorts
NMOSD MS HC
No. of patients (N) 28 60 62
No. of eyes (N) 52 116 123
Sex (female) (N [%])a 26 (93%) 55 (92%) 56 (90%)
Age (y) (mean ± SD)b 43.6 ± 11.5 39.0 ± 10.9 41.7 ± 13.5
Patients with a history of ON (N [%]) 16 (57%) 29 (48%) —
Eyes with a history of ON (N [%])c 20 (38%) 32 (28%) —
Number of ONs per eye (median [range]) 1.5 (1–8) 1 (1–2) —
VA for ON eyes (logMAR) (mean ± SD)d 0.36 ± 0.69 −0.09 ± 0.10
EDSS score (median [range]) 3 (0–6.5) 2 (0–4.5) —
Disease duration (y) (mean ± SD) 6.8 ± 4.8 7.9 ± 8.4 —
pRNFL (μm) (mean ± SD) 81.2 ± 22.1 90.8 ± 15.3 97.6 ± 8.8
GCIPL (mm3) (mean ± SD) 1.69 ± 0.29 1.83 ± 0.24 1.94 ± 0.14
INL (mm3) (mean ± SD) 0.94 ± 0.09 0.96 ± 0.06 0.95 ± 0.06
FT (μm) (mean ± SD) 262.9 ± 14.9 272.1 ± 20.3 272.3 ± 23.1
Abbreviations: EDSS = ExpandedDisability Status Scale; FT = foveal thickness; GCIPL = combinedmacular ganglion cell and inner plexiform layer volume; HC =
healthy controls; INL = inner nuclear layer volume; logMAR = logarithm of the minimum angle of resolution; NMOSD = neuromyelitis optica spectrum
disorders; ON = optic neuritis; pRNFL = peripapillary retinal nerve fiber layer thickness; VA = high-contrast visual acuity.
a Sex match: p value = 1.
b Age match: p value: HC vs MS = 0.382, HC vs NMOSD = 0.437, MS vs NMOSD = 0.056.
c ON match: p value = 0.199.
d VA measurements for 25 (78%) ON eyes of patients with MS and 17 (85%) ON eyes of patients with NMOSD were available.
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characteristic (ROC) curves. All linear regression analyses
were performed using linear mixed-effect models including
intereye within-patient correlations, age, and sex as random
effects. The marginal and conditional coefficients of de-
termination of the linear models were calculated with pseudo
R-squared. Stepwise logistic regression analysis for model se-
lection was performed by the Akaike InformationCriteria with
both backward and forward modes of stepwise search based
on generalized linear models. In this exploratory study, we
corrected p values for multiple testing using the Benjamini-
Hochberg procedure. In addition, the identified parameter
differences were tested in a second independent cohort
obtained with the same scanning protocol at a different center.
One-sided p values were reported for the confirmatory cohort,
not corrected for multiple testing. Sample size for the confir-
matory cohort was calculated for 1-sided 2-sample t-test with
90% power and a significance level of 0.05. To adjust this
estimate for eye-based statistics, we added 60% sample size to
account for intereye within-patient effects and additional
covariates. All statistical analysis were performed in R version
3.5.023 with packages stats, lme4, lmerTest, MuMIn, ROCR,
ggplot2, plotROC, pwr, multcomp, and ggpubr packages. The
p values less than 0.05 were considered significant.
Data availability
All data are available on reasonable request from the corre-
sponding author.
Results
Foveal shape changes in NMOSD and MS
First, we analyzed foveal shape in patients with NMOSD and
MS and compared results with measurements in HCs. Foveal
shape was altered in patients with NMOSD, but only mildly
affected in patients with MS, both in comparison to HCs (table
2). Foveal parameters stratified by history of ON are included
in supplemental data (table e-2, links.lww.com/NXI/A271).
In contrast, both patients with MS and NMOSD showed
neuroaxonal damage typically occurring after ON: pRNFL and
GCIPL were lower in patients with NMOSD in comparison to
HCs (pRNFL: standard error of B [SE] = −17.7 [3.0] μm,
p < 0.001, GCIPL: B [SE] = −0.27 [0.04] mm3, p < 0.001), but
also in patients with MS in comparison to HCs (pRNFL: B
[SE] = −7.0 (2.0) μm, p < 0.001, GCIPL: B [SE] = −0.12 [0.03]
mm3, p = 0.001).
Parameter selection
Next, we selected parameters with the highest potential to be
abnormal in NMOSD: We therefore analyzed parameter
performance in discriminating between eyes from patients
with NMOSD and MS, regardless of ON status (table 3 and
figure 2A). This was followed by a linear regression analysis
against diagnosis, history of ON, and their interaction effect to
derive effect sizes and group differences accounting for ON.
Figure 1 Three-dimensional foveal shape analysis method overview
(A) ILM surface smoothing and radial reconstruction using the cubic Bezier polynomial. (B) Rim height, average pit depth, and central foveal thickness. (C) Rim
disk (blue), slope disk (red), and pit flat disk (green) and major and minor axes on each surface. (D) Rim volume, pit volume, and inner rim volume. APD =
average pit depth, CFT = central foveal thickness; ILM = inner limiting membrane; major = major axis; minor = minor axis.
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Table 3 shows the results of this selection process, ordered by
AUC. The best parameter selected from the ROC analysis was
pit flat disk area (AUC= 0.798, figure 2A). To derive a final set
of relevant parameters, we computed a stepwise logistic re-
gression model to predict NMOSD vs MS, including only the
parameters with AUC ≥0.7. This selected 4 parameters: pit
flat disk area, average pit flat disk diameter, inner rim volume,
and major slope disk length (figure 2, D–G).
Association with ON and neuroaxonal damage
A crucial question is whether these parameters react to ON-
related damage or are indeed at least partially independent. To
further investigate this, we repeated the AUC analysis, but this
time separately for the eyes without a history of ON (ON−) and
the ON+ (table e-2, links.lww.com/NXI/A271). Indeed, foveal
shape was altered also in the ON−. Here, the best foveal shape
parameter to distinguish ON− from patients with NMOSD and
patients with MS was minor pit flat disk length (AUC = 0.804,
figure 2B). In ON+, the best-performing parameter to discrim-
inate between patients with NMOSD and patients with MS was
major pit flat disk length (AUC = 0.817, figure 2C). Of note,
NMOSD ON− also showed signs of mild neuroaxonal damage
comparedwithHC (pRNFL: B [SE] = −5.7 [2.4] μm, p= 0.017;
GCIPL: B [SE] = −0.12 [0.04] mm3, p = 0.001).
Table 2 Foveal shape analysis parameters results (mean ± SD) and linear regression analysis for NMOSD and MS vs HC
HC (mean ±
SD)
MS (mean ±
SD)
NMOSD (mean ±
SD)
HC vs NMOSD HC vs MS
B (SE) p B (SE) p
Average pit depth (mm) 0.117 ± 0.021 0.111 ± 0.018 0.101 ± 0.026 −0.017
(0.005)
<0.001 −0.006 (0.003) 0.078
Central foveal thickness (mm) 0.231 ± 0.015 0.229 ± 0.017 0.228 ± 0.017 −0.004
(0.004)
0.330 −0.002 (0.003) 0.535
Average rim height (mm) 0.348 ± 0.014 0.340 ± 0.016 0.328 ± 0.018 −0.021
(0.003)
<0.001 −0.009 (0.002) <0.001
Average rim disk diameter (mm) 2.184 ± 0.115 2.152 ± 0.110 2.132 ± 0.130 −0.056
(0.027)
0.037 −0.034 (0.020) 0.082
Rim disk area (mm2) 3.717 ± 0.387 3.606 ± 0.371 3.545 ± 0.436 −0.184
(0.090)
0.041 −0.116 (0.066) 0.079
Major rim disk length (mm) 0.630 ± 0.066 0.613 ± 0.063 0.600 ± 0.075 −0.032
(0.015)
0.039 −0.018 (0.011) 0.112
Minor rim disk length (mm) 0.619 ± 0.065 0.599 ± 0.062 0.590 ± 0.072 −0.030
(0.015)
0.042 −0.021 (0.011) 0.055
Average slope disk diameter (mm) 0.663 ± 0.119 0.653 ± 0.152 0.771 ± 0.136 0.104 (0.028) <0.001 −0.012 (0.025) 0.626
Slope disk area (mm2) 0.361 ± 0.131 0.358 ± 0.180 0.486 ± 0.164 0.120 (0.032) <0.001 −0.005 (0.028) 0.858
Major slope disk length (mm) 0.068 ± 0.025 0.068 ± 0.034 0.090 ± 0.029 0.021 (0.006) <0.001 −4.8e−4 (0.005) 0.930
Minor slope disk length (mm) 0.053 ± 0.019 0.052 ± 0.026 0.072 ± 0.026 0.019 (0.005) <0.001 −0.001 (0.004) 0.772
Average pit flat disk diameter
(mm)
0.215 ± 0.030 0.211 ± 0.039 0.257 ± 0.052 0.042 (0.008) <0.001 −0.005 (0.006) 0.440
Pit flat disk area (mm2) 0.037 ± 0.010 0.036 ± 0.015 0.054 ± 0.025 0.017 (0.003) <0.001 −0.001 (0.002) 0.691
Major pit flat disk length (mm) 0.0067 ±
0.0018
0.0065 ±
0.0027
0.0098 ± 0.0048 0.0032
(0.0007)
<0.001 −0.0001
(0.0004)
0.725
Minor pit flat disk length (mm) 0.0058 ±
0.0016
0.0056 ±
0.0023
0.0083 ± 0.0036 0.0026
(0.0005)
<0.001 −0.0002
(0.0004)
0.628
Rim volume (mm3) 1.045 ± 0.153 0.983 ± 0.133 0.910 ± 0.170 −0.141
(0.036)
<0.001 −0.061 (0.025) 0.013
Inner rim volume (mm3) 0.104 ± 0.018 0.103 ± 0.019 0.088 ± 0.015 −0.017
(0.004)
<0.001 −0.001 (0.003) 0.753
Pit volume (mm3) 0.252 ± 0.043 0.246 ± 0.051 0.259 ± 0.044 0.005 (0.010) 0.606 −0.007 (0.008) 0.402
Average maximum pit slope
(degrees)
12.16 ± 3.38 11.10 ± 2.41 9.86 ± 3.11 −2.42 (0.74) 0.001 −1.03 (0.52) 0.047
Abbreviations: B = estimate; HC = healthy controls; MS = patients with MS; NMOSD = patients with neuromyelitis optica spectrum disorders; SE = standard
error of B.
Significant p values are marked in bold.
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Foveal changes may also be driven not by ON per se, but by
the amount of neuroaxonal damage after ON. Here, MS may
be a problematic control group because the amount of ON-
related retinal damage is typically lesser than in NMOSD.10,24
To investigate whether differences in neuroaxonal damage are
indeed able to explain the observed foveal differences, we
repeated the linear regression model analyses for the pre-
viously selected 4 parameters, but this time corrected addi-
tionally for GCIPL and INL (table 4), which can be
considered sensitive parameters for ON severity. Here, it was
confirmed that the observed group differences are unlikely to
be explained by ON severity differences alone.
See supplemental data for more results on regression analysis
corrected for the neuroaxonal damage (table e-3, links.lww.
com/NXI/A272). Figure 2, H–I shows rim volume and av-
erage pit depth as example foveal shape parameters signifi-
cantly dependent onON status but not on diagnosis. Figure 2,
Table 3 AUC and linear regression analysis results for NMOSD vs MS, sorted in ascending order of AUC
NMOSD vs MS
(AUC)
Linear regression with interaction effects of diagnosis and ON history
MS vs NMOSD ON2 vs ON+ NMOSD × ON
R2Marg R
2
CondB (SE) p B (SE) p B (SE) p
Pit flat disk area (mm2) 0.798 0.011 (0.005) 0.021 0.001 (0.002) 0.544 0.015 (0.004) 0.001 0.176 0.843
Average pit flat disk diameter
(mm)
0.796 0.033 (0.011) 0.002 0.004 (0.005) 0.423 0.029 (0.009) 0.002 0.200 0.876
Minor pit flat disk length (mm) 0.796 0.0018
(0.0007)
0.011 0.0002
(0.0003)
0.645 0.0020
(0.0007)
0.007 0.172 0.827
Major pit flat disk length (mm) 0.790 0.0019
(0.0009)
0.038 0.0003
(0.0004)
0.456 0.0031
(0.0008)
<0.001 0.177 0.855
Inner rim volume (mm3) 0.755 −0.012
(0.004)
0.006 −0.002
(0.001)
0.170 −0.007
(0.003)
0.006 0.144 0.940
Minor slope disk length (mm) 0.744 0.017 (0.006) 0.013 0.001 (0.002) 0.554 0.008 (0.004) 0.051 0.111 0.941
Slope disk area (mm2) 0.739 0.102 (0.042) 0.022 0.010 (0.011) 0.371 0.053 (0.022) 0.022 0.096 0.958
Average slope disk diameter
(mm)
0.739 0.094 (0.035) 0.010 0.006 (0.009) 0.509 0.050 (0.019) 0.010 0.116 0.956
Major slope disk length (mm) 0.733 0.017 (0.008) 0.040 0.002 (0.002) 0.265 0.010 (0.004) 0.019 0.083 0.963
Average rim height (mm) 0.664 −0.008
(0.003)
0.022 −0.007
(0.002)
0.001 −0.009
(0.004)
0.022 0.107 0.882
Rim volume (mm3) 0.627 −0.053
(0.032)
0.124 −0.061
(0.016)
<0.001 −0.044
(0.032)
0.164 0.081 0.878
Average pit depth (mm) 0.602 −0.007
(0.005)
0.147 −0.007
(0.002)
<0.001 −0.009
(0.004)
0.025 0.069 0.931
Pit volume (mm3) 0.594 0.012 (0.011) 0.369 −0.006
(0.004)
0.239 0.002 (0.008) 0.845 0.013 0.917
Average maximum pit slope
(degrees)
0.593 −0.74 (0.59) 0.210 −0.73 (0.26) 0.008 −1.24 (0.51) 0.019 0.073 0.908
Major rim disk length (mm) 0.556 −0.010
(0.015)
0.671 −0.021
(0.006)
0.002 −0.005
(0.013)
0.697 0.025 0.902
Average rim disk diameter
(mm)
0.550 −0.014
(0.026)
0.657 −0.039
(0.012)
0.002 −0.010
(0.023)
0.657 0.027 0.891
Rim disk area (mm2) 0.549 −0.043
(0.088)
0.628 −0.128
(0.039)
0.002 −0.038
(0.077)
0.628 0.027 0.892
Minor rim disk length (mm) 0.545 −0.004
(0.015)
0.761 −0.022
(0.007)
0.002 −0.008
(0.013)
0.756 0.029 0.878
Central foveal thickness (mm) 0.543 −0.001
(0.004)
0.891 1.5e−4
(0.001)
0.891 −0.001
(0.002)
0.891 0.002 0.946
Abbreviations: AUC = area under the curve; B = estimate; MS = patients with MS; NMOSD = patients with neuromyelitis optica spectrum disorders; NMOSD ×
ON = interaction effect of diagnosis andON; ON = optic neuritis; ON− = eyes without a history of ON; ON+ = eyes with a history of ON; SE = standard error of B;
R2Cond = conditional R-squared; R
2
Marg = marginal R-squared.
Significant p values and AUC ≥0.7 are marked in bold.
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Figure 2 ROC curves, exploratory data analysis for selected parameters, and sample fovea
ROC curves for best-performing foveal shape and standard OCT parameters discriminating between (A) NMOSD vs MS, (B) NMOSD ON− vs MS ON−, and (C)
NMOSDON + vsMSON+. Box and dot plots for (D) pit flat disk area, (E) average pit flat disk diameter, (F) inner rim volume, and (G)major slope disk length, the
selected 4 foveal shape parameters. (H) Rim volume and (I) average pit depth, as example foveal shape parameters affected by ON but not diagnosis. A
sample central (foveal) B scan of (J) MS ON− and (K) NMOSD ON−, chosen from the median of the selected pit flat disk parameters in each group,
demonstrating the difference in foveal pit (pit flat disk), between NMOSD and MS in eyes without a history of ON. AUC = area under the curve; FT = foveal
thickness; pRNFL = peripapillary retinal nerve fiber layer thickness; INL = inner nuclear layer volume; HC = healthy controls; MS = patients with MS; NMOSD =
patients with neuromyelitis optica spectrum disorders; ON = optic neuritis; ON− = eyes without a history of ON; ON+ = eyes with a history of ON; ROC =
receiver operating characteristic.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 5 | September 2020 7
J–K shows sample central B scans (crossing the fovea) of
ON− from patients with NMOSD and MS, chosen from the
median of the selected pit flat disk parameters in each group.
Parameter confirmation
Finally, we tested whether the parameters identified in the ex-
ploratory analysis could be confirmed in an independent cohort
of patients with NMOSD and MS measured with the same
device and protocol at an independent center. Based on dif-
ferences in the selected parameters, we determined the mini-
mum sample size for a confirmatory cohort as n = 38, 29, 35,
and 59 eyes per group, based on measurements for pit flat disk
area, average pit flat disk diameter, inner rim volume, and major
slope disk length, respectively. In this confirmatory cohort, pit
flat disk area and average pit flat disk diameter were confirmed
to be significantly different inNMOSD in comparison toMS (B
[SE] = 0.007 [0.004] mm2, p = 0.035 and B [SE] = 0.018
[0.010]mm, p = 0.039, respectively), neither dependent onON
(p = 0.254 and 0.184) nor on NMOSD-specific ON (p = 0.293
and 0.382). Differences in inner rim volume were not significant
in the confirmatory cohort (diagnosis: p = 0.125; ON: p =
0.080; NMOSD-specific ON: p = 0.056). Major slope disk
length only showed a significant association with NMOSD-
specific ON (diagnosis: p = 0.155; ON history: p = 0.370;
NMOSD-specific ON: B [SE] = 0.012 [0.007] mm, p = 0.046).
Discussion
Using a novel foveal morphometry approach, we here show
that foveal shape is altered in patients with AQP4-
IgG–seropositive NMOSD. Our results further support that
these changes cannot be explained by neuroaxonal damage
resulting from ON alone.
Foveal morphometry described a flatter and wider fovea in
AQP4-IgG–seropositive NMOSD both in comparison to MS
and HC (figure 2, J–K). This is characterized by increased pit
flat disk area, increased average pit flat disk diameter, reduced
inner rim volume, and increased major slope disk length. Al-
though neuroaxonal damage from ON altered the foveal shape
as well, we observed robust changes in these parameters also in
eyes never experiencing anON and when correcting for ON or
neuroaxonal damage in the statistical models in all eyes.
The foveal shape changes in AQP4-IgG–seropositive NMOSD
reported in our study are supported by previous studies, which
investigated thickness or volume changes as indirect evidence
for foveal shape changes. Jeong et al.16 and Oertel et al.17
showed a significant reduction in FT in eyes of patients with
AQP4-IgG–seropositive NMOSD independent of ON in
comparison to HCs.
Table 4 Linear regression results for the selected foveal shape analysis parameters corrected for GCIPL and INL
Linear regression with interaction effects of diagnosis and ON history corrected for GCIPL
MS vs NMOSD ON2 vs ON+ GCIPL (mm3) NMOSD × ON
R2Marg R
2
CondB (SE) p B (SE) p B (SE) p B (SE) p
Pit flat disk area (mm2) 0.010
(0.005)
0.031 −3.2e−4
(0.002)
0.886 −0.016
(0.006)
0.010 0.012
(0.004)
0.010 0.212 0.858
Average pit flat disk diameter
(mm)
0.030
(0.011)
0.006 −8.3e−5
(0.005)
0.986 −0.038
(0.013)
0.006 0.023
(0.009)
0.019 0.230 0.889
Inner rim volume (mm3) −0.011
(0.004)
0.013 −7.7e−4
(0.001)
0.554 0.010
(0.004)
0.013 −0.006
(0.003)
0.038 0.159 0.945
Major slope disk length (mm) 0.017
(0.008)
0.051 0.002 (0.002) 0.360 5.5e−5
(0.006)
0.992 0.010
(0.004)
0.033 0.082 0.962
Linear regression with interaction effects of diagnosis and ON history corrected for INL
MS vs NMOSD ON2 vs ON+ INL (mm3) NMOSD × ON
R2Marg R
2
CondB (SE) p B (SE) p B (SE) p B (SE) p
Pit flat disk area (mm2) 0.012
(0.005)
0.017 0.001
(0.002)
0.771 0.041
(0.024)
0.145 0.013
(0.004)
0.014 0.193 0.851
Average pit flat disk diameter
(mm)
0.035
(0.011)
0.005 0.003
(0.005)
0.482 0.075
(0.054)
0.200 0.027
(0.010)
0.013 0.208 0.882
Inner rim volume (mm3) −0.012
(0.004)
0.009 −0.002
(0.001)
0.212 0.003
(0.018)
0.860 −0.008
(0.003)
0.009 0.143 0.939
Major slope disk length (mm) 0.016
(0.008)
0.061 0.002
(0.002)
0.312 −0.014
(0.028)
0.623 0.010
(0.004)
0.022 0.083 0.962
Abbreviations: B = estimate; GCIPL = combined macular ganglion cell and inner plexiform layer volume; INL = inner nuclear layer volume; MS = patients with
MS; NMOSD = patients with neuromyelitis optica spectrum disorders; NMOSD × ON = interaction effect of diagnosis and ON; ON = optic neuritis; ON− = eyes
without a history of ON; ON+ = eyes with a history of ON; SE = standard error of B; R2Cond = conditional R-squared; R
2
Marg = marginal R-squared.
Significant p values are marked in bold.
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Apathophysiologic explanation for the observed changes could be
the presence of a primary retinopathy in AQP4-IgG–seropositive
NMOSD, mediated by AQP4-IgG. The principal glial cell of the
retina is the Mu¨ller cell, expresses AQP4, and is enriched around
the fovea.25 Mu¨ller cell bodies reside in the INL, but process
stretch through the whole thickness of the retina, linking retinal
neurons and photoreceptors with blood vessels. Importantly, an-
imal studies have shown complement-independent AQP4 loss in
Mu¨ller cells in rats induced by AQP4-IgG, which is in line with an
AQP4-IgG–mediated primary retinopathy in NMOSD.26,27
AQP4-IgG–mediated primary retinal astrocytopathy has been
also suggested in human by AQP4-IgG–seropositive NMOSD
autopsy cases.28 AQP4 is expressed in Mu¨ller cell end feet—
analogous to astrocytic end feet—at the blood-retina barrier.29
For AQP4-IgG circulating in serum to reach its antigen, the blood-
retina barrier presumably needs to be disrupted. Blood-retina or
-brain barrier disruptions are typically associated with an acute
inflammatory event and then conceptionally linked to an acute
attack involving complement.30 It is unclear whether or to which
extent blood-retina/brain barrier disruptions occur in NMOSD
and other diseases that do not lead to full attack cascades. A recent
analysis of the NMOSD momentum trial data31 revealed that
elevated glial fibrillary acidic protein levels in serum were associ-
ated with an increased attack risk, independently suggesting that
there is indeed subclinical astrocyte damage outside attacks (An-
nual European Committee for Treatment and Research in Mul-
tiple Sclerosis [ECTRIMS] 2019, P1609).32 A recent study could
further show that in rats, blood-brain barrier breakdown is not
necessary for NMOSD pathology, but that NMOSD-like disease
can be caused by AQP4-IgG circulating in CSF.33 We recently
reported progressive GCIPL loss without ON in a longitudinal
study investigating an overlapping cohort.34 Further evidence for
a primary retinopathy comes from Tian et al.35 reporting inner
retinal layer thinning independent from ON. Significant changes
in vascularization of the fovea were also shown in patients with
AQP4-IgG–seropositive NMOSD in comparison to HCs using
OCT angiography.36–38
Alternatively, foveal changes could be caused by subclinical
ON. Occasionally, studies have reported neuroaxonal damage
also in eyes without prior ON in AQP4-IgG–seropositive
NMOSD, which could be interpreted as evidence as such.39
However, earlier studies had cohort heterogeneity due to
incomplete antibody characterization or inclusion of patients
with antibody-negative NMOSD. Furthermore, ON in
NMOSD often occurs near the chiasm, and neuroaxonal
damage can be caused by chiasmal crossover from an affected
eye to the fellow eye,40 which might not be clinically apparent.
In this study, we found evidence of neuroaxonal damage also
in eyes reported to have never experienced ON, which is in
agreement with our recent findings in a multicenter study.34 It
is possible that our data set also included fellow eyes that were
affected from cross-chiasmal affects during a contralateral ON.
The number of patients with NMOSD only experiencing
transverse myelitis and no ON was too small, which is why we
refrained from analyzing eyes of these patients separately. In
consequence, we cannot fully determine to which extent the
observed changes may be caused or affected by covert ON and
neuroaxonal damage of the optic nerve.
Themain limitationof our studywas the low sample size forAQP4-
IgG–seropositiveNMOSD, especially for patients without a history
of ON, which is unfortunately common in studies investigating
NMOSD. Another limitation of this study is that the diagnostic
value is unclear, as we only used scans from 1 OCT device using
a single scanning protocol. It is unclear how scans from different
OCT devices and scanning protocols can be compared.
Foveal morphometry may potentially be useful for differential
diagnosis of AQP4-IgG–seropositive NMOSD. Typically,
pRNFL and GCIPL as well as other OCT parameters associ-
ated with neuroaxonal damage are mostly nonspecific to the
underlying ON etiology. In contrast, many foveal morphom-
etry parameters showed significant differences between
patients with NMOSD and MS in this study. Parameter se-
lection resulted in 4 promising parameters describing foveal
differences: pit flat disk area, average pit flat disk diameter,
major slope disk length, and inner rim volume. Only the first 2
parameters could be confirmed in an independent cohort. The
reason may be the different frequency of ON in the confir-
matory cohort between patients with MS and NMOSD, which
exemplifies the need for additional confirmation, especially in
eyes that are inconspicuous in regard to neuroaxonal damage
from ON. Future work should further investigate this by
comparing patients with myelin oligodendrocyte glycoprotein
(MOG)-IgG–seropositive disease against patients withMOG/
AQP4-IgG double-negative NMOSD, as well as clarify effects
of scan protocols and foveal variability in healthy persons.
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